"Orally Disintegrating Solid Pharmaceutical Dosage Unit Containing a Partus Control Substance" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors PLATTEEUW, Johannes Jan; COELINGH BENNINK, Herman Jan Tijmen, filed on September 29, 2015, was made available onli
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Antimicrobial Drugs Advisory Committee to discuss new drug application 209367, ciprofloxacin inhalation powder, sponsored by Bayer HealthCare Pharmaceuticals, Inc., for the proposed indication of reduction of exacerbations in non-cystic fibrosis...
By a News Reporter-Staff News Editor at Pharma Business Week Medicure Inc., a specialty pharmaceutical company, announced that, through its subsidiary, Medicure International Inc., it has acquired an exclusive license to sell and market PREXXARTAN oral solution in the United States and its territories from Carmel Biosciences, Inc. for a seven
DALLAS- Neos Therapeutics, Inc., a pharmaceutical company focused on developing, manufacturing, and commercializing innovative extended-release products using its proprietary modified-release drug delivery and orally disintegrating tablet technology platforms, today announced that Vipin K. Garg, Ph.D., President and CEO of Neos Therapeutics, will..
By a News Reporter-Staff News Editor at Clinical Trials Week Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, announced the launch of NovaTears in New Zealand and registrational approval in Australia. In March 2017, Nova
Novartis submits application to FDA for Kymriah tisagenlecleucel in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy. In August 2017, Kymriah became the first available chimeric antigen receptor T cell therapy when it received FDA approval five weeks prior to its PDUFA date and was launched for pati
By a News Reporter-Staff News Editor at Diabetes Week CHAPEL HILL, NC- Treating type 1 diabetes and some cases of type 2 diabetes has long required painful and frequent insulin injections or a mechanical insulin pump for insulin infusion. "Our plan now is to further optimize and test these synthetic cells in larger animals, develop a skin patch
By a News Reporter-Staff News Editor at Pharma Business Week Teva Pharmaceutical Industries Ltd., announced it has completed the divestiture of PARAGARD to CooperSurgical in a $1.1 billion cash transaction. "We now have an infusion of $1.1 billion to progress the repayment of term loan debt and are on track to deliver on our promise to genera
By a News Reporter-Staff News Editor at Pharma Business Week Teva Pharmaceutical Industries Ltd., announced that the United States District Court for the District of Delaware has ruled in the Company's favor in patent litigation involving Teva's abbreviated new drug application directed to a generic version of Valeant's Uceris tablets.
New Findings in Transdermal Delivery Described from Toho University. By a News Reporter-Staff News Editor at Heart Disease Weekly A new study on Drugs and Therapies- Transdermal Delivery is now available. The news correspondents obtained a quote from the research from Toho University, "Recently, the bisoprolol patch, a novel transdermal beta 1- b
-Mesoblast Limited today announced that results from the randomized, placebo-controlled Phase 2 trial of its proprietary allogeneic mesenchymal precursor cells over 52 weeks in patients with biologic refractory rheumatoid arthritis were presented at the 2017 American College of Rheumatology Annual Meeting held this week in San Diego, CA..
Amgen and Allergan plc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin . "ABP 215 has the potential to provide healthcare professionals and appropriate patients across Europe access to hig
10 November 2017 11:35 GMT. AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the marketing authorisation of benralizumab as an add-on maintenance treatment in adult patien
Benralizumab uniquely targets and rapidly depletes eosinophils and is the first respiratory biologic with an 8- week maintenance dosing schedule. AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positiv
Beximco Pharmaceuticals Limited, the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces it has commenced the export of Sotalol Hydrochloride, a generic version of the cardiovascular drug Betapace, to the US. With the export of our first product to the US in August 2016, we began a new
NEW YORK CITY- Bristol-Myers Squibb Co. announced the U.S. Food and Drug Administration has expanded the indication for Sprycel or dasatinib tablets to include the treatment of children with Philadelphia chromosome-positive or Ph+ chronic myeloid leukemia or CML in chronic phase or CP. As part of its commitment to children and adolescents with canc
Data on Drug Delivery Systems Reported by Researchers at University of Minnesota. According to news reporting out of Minneapolis, Minnesota, by NewsRx editors, research stated, "The primary focus of this research is the design of wall-driven peristaltic pumps based on first principles with minimal simplifying assumptions and implementation by numer
By a News Reporter-Staff News Editor at Drug Week E Ink Holdings, "E Ink", the leading innovator of electronic ink technology and LTS Lohmann-Therapie Systeme AG, "LTS" leading in the development and manufacturing of transdermal therapeutic systems, announced their partnership to develop a "Smart Patch" prototype. The Smart Patch prototype is a t
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today initial clinical data from the ongoing VOYAGE Phase 1 study of FATE- NK100 as a monotherapy for the treatment of refractory or relapsed acute myelogenous leukemia.
Findings from Kyushu University Provides New Data on Drug Delivery Systems. According to news reporting out of Fukuoka, Japan, by NewsRx editors, research stated, "Administration of drugs and other therapeutic agents has been the central strategy of contemporary medicine for cardiovascular disease. Our news journalists obtained a quote from the res
InfuSystem Holdings, Inc., a leading national provider of infusion pumps and related services for the healthcare industry in the United States, today reported financial results for the quarter ended September 30, 2017. Net revenues totaled $17.6 million, an increase of 2.1%, versus the third quarter of 2016 of $17.2 million Rental revenues increa
Our news editors obtained a quote from the research from the Department of Chemistry, "The dynamic release of Doxycycline was investigated in the physiological fluids at 37 degrees C. Various kinetic models such as Power function model, Schott model and Higuchi model were applied to interpret the release data. For more information on this research
According to news reporting originating in Cordoba, Argentina, by NewsRx journalists, research stated, "The bioadhesive polymeric films as topical drug delivery systems are interesting alternatives to improve the pharmacotherapy and patient compliances. The news reporters obtained a quote from the research from Cordoba National University, "Relevan
By a News Reporter-Staff News Editor at Drug Week Research findings on Drugs and Therapies- Drug Delivery Systems are discussed in a new report. According to news reporting originating from Tiruchirappalli, India, by NewsRx correspondents, research stated, "In this work, solid silicon microneedles with a higher aspect ratio and sharper tips are f
Novaer Holdings, Bedminster, New Jersey, has been assigned a patent developed by three co-inventors for "drug delivery devices for delivery of ocular therapeutic agents." The co-inventors are Casey Kopczynski, Chapel Hill, North Carolina, Cheng-Wen Lin, Durham, North Carolina, and Chris Sutay, Raleigh, North Carolina. Written by Amal Ahmed; edited